DSGN vs. NAGE, MENS, SION, REPL, GHRS, XERS, SNDX, TRVI, CMRX, and CRON
Should you be buying Design Therapeutics stock or one of its competitors? The main competitors of Design Therapeutics include Niagen Bioscience (NAGE), Jyong Biotech (MENS), Sionna Therapeutics (SION), Replimune Group (REPL), GH Research (GHRS), Xeris Biopharma (XERS), Syndax Pharmaceuticals (SNDX), Trevi Therapeutics (TRVI), Chimerix (CMRX), and Cronos Group (CRON). These companies are all part of the "pharmaceutical products" industry.
Design Therapeutics vs. Its Competitors
Design Therapeutics (NASDAQ:DSGN) and Niagen Bioscience (NASDAQ:NAGE) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.
In the previous week, Niagen Bioscience had 6 more articles in the media than Design Therapeutics. MarketBeat recorded 7 mentions for Niagen Bioscience and 1 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 0.75 beat Niagen Bioscience's score of 0.49 indicating that Design Therapeutics is being referred to more favorably in the media.
Niagen Bioscience has a net margin of 13.07% compared to Design Therapeutics' net margin of 0.00%. Niagen Bioscience's return on equity of 19.06% beat Design Therapeutics' return on equity.
Niagen Bioscience has higher revenue and earnings than Design Therapeutics. Design Therapeutics is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.
Design Therapeutics presently has a consensus target price of $4.00, suggesting a potential upside of 0.50%. Niagen Bioscience has a consensus target price of $13.22, suggesting a potential upside of 30.12%. Given Niagen Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Niagen Bioscience is more favorable than Design Therapeutics.
56.6% of Design Therapeutics shares are held by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are held by institutional investors. 31.2% of Design Therapeutics shares are held by insiders. Comparatively, 9.4% of Niagen Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Design Therapeutics has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500. Comparatively, Niagen Bioscience has a beta of 2.14, suggesting that its share price is 114% more volatile than the S&P 500.
Summary
Niagen Bioscience beats Design Therapeutics on 12 of the 15 factors compared between the two stocks.
Get Design Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DSGN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding DSGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Design Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:DSGN) was last updated on 7/19/2025 by MarketBeat.com Staff
Free DSGN Stock Alerts